CAR T Vision shared a post on LinkedIn:
“Access to CAR T-cell therapy remains one of the defining challenges and opportunities in Cancer Care today.
Join us at TANDEM 2026 in Salt Lake City, February 6, 11:30am–12:30pm MST, for a Product and Innovation session to discuss what it will take to double the proportion of eligible patients treated with CAR T-cell therapy by 2030.
The session will feature short talks from CAR T Vision Steering Committee members Miguel-Angel Perales, and David Schmahl, alongside best-practice case studies from David Porter and Navneet Majhail, discussing real-world approaches to overcoming access barriers.
Together we can help ensure every eligible patient gets the opportunity for cure with CAR T-cell therapy.”
Navneet Majhail, Physician-in-Chief of Blood Cancers at Sarah Cannon Cancer Network, shared this post, adding:
“Appreciate the invite from CAR T Vision initiative to discuss barriers and opportunities to enhancing access to CARTcell therapies. Looking forward to sharing innovative care models we are exploring through HCA Healthcare Sarah Cannon Transplant and Cellular Therapy Network to support administration of these therapies at community oncology sites.”
More posts featuring Navneet Majhail.